Dyne Therapeutics, Inc.
z-rostudirsen
Duchenne muscular dystrophy
Resolved
7days ago
Phase 3 readout · Jun 30, 2026
What's at stake
Phase 3 trial results for z-rostudirsen in Duchenne muscular dystrophy are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“plans to initiate a global confirmatory Phase 3 clinical trial of z-rostudirsen in Q2 2026.”